In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharma (NASDAQ:KERX) and raised his price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a price target …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and raised the price …
In a research note released Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a $24 price target, following today’s FDA approval …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $30 price target. The report comes ahead of the FDA’s long-anticipated …
In a research note released this morning, Maxim Group analyst Jason Kolbert maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a $24 …
In a research note published August 8, H.C.
